<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2216-0973</journal-id>
<journal-title><![CDATA[Revista Cuidarte]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cuid]]></abbrev-journal-title>
<issn>2216-0973</issn>
<publisher>
<publisher-name><![CDATA[Programa de Enfermería, Facultad de Ciencias de la Salud, Universidad de Santander UDES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2216-09732024000200016</article-id>
<article-id pub-id-type="doi">10.15649/cuidarte.3799</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Immune thrombocytopenic purpura following mRNA-]]></article-title>
<article-title xml:lang="es"><![CDATA[Púrpura trombocitopénica autoinmune tras vacunación contra el mRNA-SARS-CoV-2: un reporte de caso]]></article-title>
<article-title xml:lang="pt"><![CDATA[Púrpura trombocitopênica autoimune após a vacinação com mRNA-SARS-CoV-2: um relato de caso]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lozada-Ramos]]></surname>
<given-names><![CDATA[Heiler]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Vega]]></surname>
<given-names><![CDATA[Ruth Aralí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torcoroma-García]]></surname>
<given-names><![CDATA[Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Santander Facultad de Ciencias Médicas y de la Salud Instituto de Investigación Masira]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Santander Facultad de Ciencias Médicas y de la Salud Instituto de Investigación Masira]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Santander Facultad de Ciencias Médicas y de la Salud Instituto de Investigación Masira]]></institution>
<addr-line><![CDATA[Bucaramanga ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2024</year>
</pub-date>
<volume>15</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2216-09732024000200016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2216-09732024000200016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2216-09732024000200016&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Herein, it is presented a case report of a Colombian adult male patient, without any previous report of thrombocytopenia or hematological disorders, who developed a mild and chronic paucisymptomatic immune thrombocytopenic purpura, a rare complication following SARS-CoV-2 m-RNA. To the best of our knowledge, this represents the first documented case in Colombia of immune thrombocytopenic purpura associated with mRNA vaccines (BNT162b2 or mRNA-1273), with a comprehensive 2-year clinical follow-up.  Case Description: The patient received the initial and second doses of the mRNA BNT162b2 vaccine in June 2021, the first booster dose in November 2021 (mRNA-1273), and the second booster dose (mRNA BNT162b2) in June 2022. Thrombocytopenia (&lt;100 x109 platelets/L, which is the criterion to define immune thrombocytopenic purpura) was documented after the second vaccination dose and both boosters, and it improved after corticosteroid therapy. However, cycling thrombocytopenia persisted until the clinical follow-up in August 2023, with platelet count ranging from 57 to 191 x109 platelets/L (mean: 103 x109 platelets/L).  Conclusion: Given that secondary immune thrombocytopenic purpura can occur following SARS-CoV-2 mRNA vaccination, systematic research to identify risk factors associated with immune thrombocytopenic purpura due to COVID-19 immunization should be conducted.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Este reporte presenta el caso de un paciente colombiano adulto, de sexo masculino, sin antecedentes de trombocitopenia ni trastornos hematológicos, que desarrolló una púrpura trombocitopénica autoinmune paucisintomática leve y crónica, una rara complicación posterior a la vacunación con ARNm contra el virus SARS-CoV-2. Hasta donde se sabe, este es el primer caso documentado en Colombia de púrpura trombocitopénica autoinmune asociada al uso de vacunas de ARNm (BNT162b2 o ARNm-1273), con un seguimiento clínico integral de 2 años.  Descripción del caso: El paciente recibió la primera y segunda dosis de la vacuna de ARNm BNT162b2 en junio de 2021, la primera dosis de refuerzo en noviembre de 2021 (ARNm-1273) y la segunda dosis de refuerzo (ARNm BNT162b2) en junio de 2022. Se documentó trombocitopenia (&lt;100 x109 plaquetas/L, que es el criterio para definir la púrpura trombocitopénica autoinmune) tras la segunda dosis y ambos refuerzos. El paciente mejoró luego del tratamiento con corticosteroides, pero la trombocitopenia cíclica persistió hasta el seguimiento clínico en agosto de 2023, con un recuento de plaquetas que oscilaba entre 57 y 191 x109 plaquetas/L (media: 103x109 plaquetas/L).  Conclusión: Dado que la púrpura trombocitopénica autoinmune puede producirse tras la vacunación con ARNm contra el virus SARS-CoV-2, es necesaria una investigación sistemática para identificar los factores de riesgo asociados a la púrpura trombocitopénica autoinmune debida a la inmunización contra la COVID-19.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdução: No presente estudo, é apresentado um relato de caso de um paciente colombiano adulto do sexo masculino, sem qualquer relato anterior de trombocitopenia ou distúrbios hematológicos, que desenvolveu uma púrpura trombocitopênica autoimune leve e crônica paucissintomática, uma complicação rara após a vacinação com mRNA dos vírus SARS-CoV-2. Até onde se sabe, esse é o primeiro caso documentado na Colômbia de púrpura trombocitopênica autoimune associada a vacinas de mRNA (BNT162b2 ou mRNA-1273), com um acompanhamento clínico abrangente de dois anos.  Descrição do caso: O paciente recebeu a dose inicial e a segunda dose da vacina mRNA BNT162b2 em junho de 2021, a primeira dose de reforço em novembro de 2021 (mRNA-1273) e a segunda dose de reforço (mRNA BNT162b2) em junho de 2022. A trombocitopenia (&lt;100 x109 plaquetas/L, que é o critério para definir púrpura trombocitopênica autoimune) foi documentada após a segunda dose de vacinação e ambos os reforços, e melhorou após a terapia com corticosteroides. No entanto, a trombocitopenia cíclica persistiu até o acompanhamento clínico em agosto de 2023, com a contagem de plaquetas variando de 57 a 191 x109 plaquetas/L (média: 103 x109 plaquetas/L).  Conclusão: Dado que a púrpura trombocitopênica autoimune secundária pode ocorrer após a vacinação com mRNA dos vírus SARS-CoV-2, deve ser realizada uma pesquisa sistemática para identificar os fatores de risco associados à púrpura trombocitopênica autoimune devido à imunização contra a COVID-19.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[COVID-19]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[mRNA Vaccines]]></kwd>
<kwd lng="en"><![CDATA[Immune Thrombocytopenic Purpura]]></kwd>
<kwd lng="en"><![CDATA[Platelets]]></kwd>
<kwd lng="es"><![CDATA[COVID-19]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[Vacunas de ARNm]]></kwd>
<kwd lng="es"><![CDATA[Púrpura Trombocitopénica Autoinmune]]></kwd>
<kwd lng="es"><![CDATA[Plaquetas]]></kwd>
<kwd lng="pt"><![CDATA[COVID-19]]></kwd>
<kwd lng="pt"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="pt"><![CDATA[Vacinas de mRNA]]></kwd>
<kwd lng="pt"><![CDATA[Púrpura Trombocitopênica Autoimune]]></kwd>
<kwd lng="pt"><![CDATA[Plaquetas]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Instituto Nacional de Salud</collab>
<article-title xml:lang=""><![CDATA[Situación COVID-19]]></article-title>
<source><![CDATA[Boletín Epidemiológico Semanal]]></source>
<year>2023</year>
<volume>52</volume>
<page-range>17</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[data.who.int. WHO Coronavirus (COVID-19) dashboard &gt;Vaccines]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alshammari]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Abuzied]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Korairi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alajlan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alzomia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[AlSheef]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bullous pemphigoid after the second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report]]></article-title>
<source><![CDATA[Ann Med Surg (Lond)]]></source>
<year>2022</year>
<volume>75</volume>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hagihara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Uchida]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ohara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Imai]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe thrombocytopenia after COVID-19 mRNA vaccination]]></article-title>
<source><![CDATA[Rinsho Ketsueki]]></source>
<year>2021</year>
<volume>62</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1684-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Towner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination]]></article-title>
<source><![CDATA[Am J Case Rep]]></source>
<year>2021</year>
<volume>22</volume>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leone]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Canovi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pilia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Casali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Depietri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fasano]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine]]></article-title>
<source><![CDATA[Thromb Res]]></source>
<year>2022</year>
<volume>211</volume>
<page-range>60-2</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sato]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Anayama]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sumi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination]]></article-title>
<source><![CDATA[Rinsho Ketsueki]]></source>
<year>2021</year>
<volume>62</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1688-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuter]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The treatment of immune thrombocytopenia (ITP): focus on thrombopoietin receptor agonists]]></article-title>
<source><![CDATA[Ann Blood]]></source>
<year>2021</year>
<volume>6</volume>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neylon]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Saunders]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Proctor]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Group]]></surname>
<given-names><![CDATA[Northern-Region Haematology]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2003</year>
<volume>122</volume>
<page-range>966-74</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Deane]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and classification of immune-mediated thrombocytopenia]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2014</year>
<volume>13</volume>
<page-range>577-83</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lozada-Ramos]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Vega]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acase report of denovoimmune thrombocytopenic purpura (ITP) following COVID-19-mRNA vaccination: 2-year clinical follow up]]></article-title>
<source><![CDATA[Mendeley Data, V2]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waxman]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Makov-Assif]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reis]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
<name>
<surname><![CDATA[Netzer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Balicer]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Dagan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing COVID- 19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel]]></article-title>
<source><![CDATA[Nat Commun]]></source>
<year>2022</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alameh]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Weissman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pardi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Messenger RNA-based vaccines against infectious diseases. Yu D, Petsch B]]></article-title>
<source><![CDATA[Curr Top Microbiol Immunol]]></source>
<year>2022</year>
<volume>440</volume>
<page-range>111-45</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharif]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Alzahrani]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Dey]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy, immunogenicity, and safety of COVID-19 vaccines: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2021</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ghanima]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune thrombocytopenia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<volume>381</volume>
<page-range>945-55</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sivaramakrishnan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine]]></article-title>
<source><![CDATA[BMJ Case Rep]]></source>
<year>2022</year>
<volume>15</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bidari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Asgarian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pour Mohammad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Naderi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Anaraki]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Gholizadeh Mesgarha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune thrombocytopenic purpura secondary to COVID-19 vaccination: A systematic review]]></article-title>
<source><![CDATA[Eur J Haematol]]></source>
<year>2023</year>
<volume>110</volume>
<page-range>335-53</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saluja]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Amisha]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gautam]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Goraya]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Systematic Review of Reported Cases of Immune Thrombocytopenia after COVID-19Vaccination]]></article-title>
<source><![CDATA[Vaccines]]></source>
<year>2022</year>
<volume>10</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1444</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Malayala]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Mohan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vasireddy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Atluri]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2021</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inagaki]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kibata]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tamaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shimizu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nomura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer]]></article-title>
<source><![CDATA[Lung Cancer]]></source>
<year>2014</year>
<volume>83</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>97-101</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Shea]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Aceves]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Dellon]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Spergel]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Furuta]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology of Eosinophilic Esophagitis]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2018</year>
<volume>154</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>333-45</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Amer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hassan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Platelet/lymphocyte ratio (PLR) predictive value in immune thrombocytopenic purpura patients]]></article-title>
<source><![CDATA[Ain Shams Med J]]></source>
<year>2023</year>
<volume>74</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>13-20</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[PX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Platelet to Lymphocyte Ratio and Glucocorticoid Resistance in Newly Diagnosed Primary Immune Thrombocytopenia: A Retrospective Cohort Study]]></article-title>
<source><![CDATA[MedSciMonit]]></source>
<year>2019</year>
<volume>25</volume>
<page-range>7321-31</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Augène]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lareyre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chikande]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guidi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ballaith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bossert]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Platelet to lymphocyte ratio as a predictive factor of 30-day mortality in patients with acute mesenteric ischemia]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2019</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
